

ANUH PHARMA LIMITED

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai-400018

Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021

(₹ in Lakhs)

Particulars	3 months ended 31/03/2021	3 months ended 31/12/2020	3 months ended 31/03/2020	12 months ended 31/03/2021	12 months ended 31/03/2020
	Audited	Unaudited	Audited	Audited	Audited
Total Revenue from Operation	9,714.69	9,833.01	7,205.25	43,196.01	30,695.96
Net Profit/(Loss) for the period before tax	166.07	469.91	(161.65)	3,855.14	1,915.56
Net Profit/(Loss) for the period after Tax	89.69	418.01	(92.00)	2,843.63	1,430.53
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	97.62	415.77	(88.85)	2,843.63	1,421.31
Paid up Equity Share Capital (face value of Rs 5/- per share)	2,505.60	2,505.60	1,252.80	2,505.60	1,252.80
Other Equity (Excluding revaluation reserve)	-	-	-	16,558.75	14,967.94
Earnings per equity share (Non annualised) (In Rs.) (Refer note no. 3 below)					
- Basic Rs.	0.18	0.83	(0.18)	5.67	2.85
- Diluted Rs.	0.18	0.83	(0.18)	5.67	2.85

1. The above is an extract of the detailed format of Financial Results for the quarter and year ended on March 31, 2021, filed with the Stock Exchange as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the quarter and year ended on March 31, 2021 is available on the Stock Exchange website viz. www.bseindia.com and on the Company's website i.e. www.anuhpharma.com.

2. Other Financial indicators

(₹ in Lakhs)

Particulars	3 months ended 31/03/2021	3 months ended 31/12/2020	3 months ended 31/03/2020	12 months ended 31/03/2021	12 months ended 31/03/2020
EBITDA	562.46	891.97	299.53	5,512.17	2,698.04
% of EBITDA Margin	5.79	9.07	4.16	12.76	8.79
EBITDA (Adjusted to Forex gain / loss and mark to market on Investment in Mutual funds)	526.37	579.51	840.32	5,372.46	3,433.09
% of Adjusted EBITDA Margin	5.42	5.89	11.66	12.44	11.18

3. On 22/09/2020, the Company passed a circular resolution for allotment of 2,50,56,000 Equity Shares of Rs. 5/- each as fully paid-up Bonus Equity Shares in the ratio of 1:1 to all registered shareholders as on the record date. Consequently, in accordance with Ind AS 33 "Earnings per Share", the basic and diluted earnings per share for all the periods presented above have been adjusted to give effect to the aforesaid issue of Bonus Shares.

4. The Board of Directors of the Company has recommended a final dividend of Rs. 1.50/- per equity share of face value of Rs.5/- each (30%), subject to shareholders' approval in the forthcoming Annual General Meeting.

For Anuh Pharma Ltd.
Sd/-
Ritesh Shah \ Vivek Shah
Joint Managing Director
(DIN: 02496729) \ (DIN: 02878724)

Place : Mumbai
Dated : May 21, 2021